title: Dexamethasone in the treatment of acute mountain sickness.
abstract: Cerebral edema occurs in fatal cases of acute mountain sickness. Dexamethasone, commonly used to treat cerebral edema due to other causes, also reduces the symptoms of acute mountain sickness when given prophylactically. However, the efficacy of dexamethasone in the treatment of established acute mountain sickness remains uncertain. To investigate this question, we exposed six men in a hypobaric chamber to a simulated altitude of 3700 m (barometric pressure, 64 kPa [481 mm Hg]) for 48 hours on two occasions. Acute mountain sickness was diagnosed with use of a symptoms questionnaire, and dexamethasone (4 mg every six hours) or placebo was then given in a randomized, double-blind, crossover fashion. Dexamethasone reduced the symptoms of acute mountain sickness by 63 percent (P less than 0.05), whereas placebo had a minimal effect (reduction by 23 percent; P not significant). In spite of this response, one subject had mild cerebral edema on brain CT after both placebo and dexamethasone. Dexamethasone had no effect on fluid shifts, oxygenation, sleep apnea, urinary catecholamine levels, the appearance of chest radiographs or perfusion scans, serum electrolyte levels, hematologic profiles, or the results of psychometric tests. Dexamethasone treatment was complicated by mild hyperglycemia in all subjects (mean [+/- SE] glucose level, 7.3 +/- 1.3 mmol per liter [132 +/- 23 mg per deciliter]). We conclude that dexamethasone effectively reduces the symptoms of acute mountain sickness. However, it did not improve objective physiologic abnormalities related to exposure to high altitudes. We therefore recommend that dexamethasone be used only when descent is impossible, or to facilitate cooperation in evacuation efforts.
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: B D
authors.initials: BD
authors.lastname: Levine
authors.forename: K
authors.initials: K
authors.lastname: Yoshimura
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Fukushima
authors.forename: T
authors.initials: T
authors.lastname: Shibamoto
authors.forename: G
authors.initials: G
authors.lastname: Ueda
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000532:Altitude Sickness / Q000188:drug therapy* / Q000503:physiopathology; D001834:Body Water / Q000378:metabolism; D001929:Brain Edema / Q000000981:diagnostic imaging; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004780:Environment, Controlled; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy*; D008297:Male; D008991:Monitoring, Physiologic; D010100:Oxygen / Q000097:blood; D011594:Psychometrics; D011897:Random Allocation; D012891:Sleep Apnea Syndromes / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D003907:Dexamethasone; D010100:Oxygen